We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Alzheimer's disease
MedXY News
EnglishTag

Alzheimer's disease

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Depression, Anxiety and PTSD Associated With Earlier Onset of Alzheimer’s Disease: Psychiatric Burden Lowers Age at Symptom Onset
NeurologyAlzheimer's diseaseEarly-onset dementia

Depression, Anxiety and PTSD Associated With Earlier Onset of Alzheimer’s Disease: Psychiatric Burden Lowers Age at Symptom Onset

By MedXY|Nov 4, 2025

In two large Alzheimer cohorts, a history of depression, anxiety, or PTSD and an increased number of psychiatric comorbidities were associated with earlier age at AD symptom onset by up to ~7–8 years for multi-morbidity.

Unlocking the Predictive Power of Plasma Biomarkers for Early Alzheimer’s Disease Detection
NeurologyAlzheimer's diseasecognitive decline

Unlocking the Predictive Power of Plasma Biomarkers for Early Alzheimer’s Disease Detection

By MedXY|Oct 27, 2025

This review evaluates recent evidence on plasma AD biomarkers, especially phosphorylated tau217 and amyloid PET, for predicting cognitive decline in unimpaired individuals, highlighting their potential and limitations.

Oral Valiltramiprosate in APOEε4/ε4 Carriers with Early Alzheimer’s Disease: Insights from the Phase III APOLLOE4 Trial
NeurologyAlzheimer's diseaseAPOEε4

Oral Valiltramiprosate in APOEε4/ε4 Carriers with Early Alzheimer’s Disease: Insights from the Phase III APOLLOE4 Trial

By MedXY|Oct 21, 2025

This phase III trial evaluated oral valiltramiprosate in APOEε4/ε4 homozygotes with early Alzheimer’s, showing brain atrophy slowing but limited overall clinical benefit, with nominal improvements in mild cognitive impairment subgroup

Molecular Interplay of TREM2 and ApoE Variants in Alzheimer’s Disease: Structural Insights and Therapeutic Implications
NeurologyAlzheimer's diseaseAPOE4

Molecular Interplay of TREM2 and ApoE Variants in Alzheimer’s Disease: Structural Insights and Therapeutic Implications

By MedXY|Oct 21, 2025

This article elucidates how TREM2-apoE3 interactions are structurally altered by Alzheimer’s-associated TREM2 R47H and apoE4 variants, revealing potential mechanisms that contribute to disease risk and informing therapeutic targeting

Obicetrapib’s Role in Modulating Alzheimer’s Disease Biomarkers in Patients with Cardiovascular Disease: A Landmark Clinical Study
CardiologyAlzheimer's diseaseAPOE4

Obicetrapib’s Role in Modulating Alzheimer’s Disease Biomarkers in Patients with Cardiovascular Disease: A Landmark Clinical Study

By MedXY|Oct 21, 2025

Obicetrapib, a CETP inhibitor, lowers Alzheimer’s biomarkers like p-tau217 in ASCVD patients, especially ApoE4 carriers, suggesting a potential preventive strategy for high-risk individuals.

Pregnancy Hypertension and Elevated p-tau217: A Midlife Indicator of Alzheimer’s Disease Risk in Women
NeurologyAlzheimer's diseasep-tau217

Pregnancy Hypertension and Elevated p-tau217: A Midlife Indicator of Alzheimer’s Disease Risk in Women

By MedXY|Oct 21, 2025

Pregnancy hypertension is independently associated with higher serum p-tau217 levels in midlife women, suggesting a link to preclinical Alzheimer’s disease pathology and potential for early screening and intervention.

Comparative Performance of Dementia Risk Indices in the HUNT Study: Insights into CogDrisk, LIBRA, CAIDE, and More
NeurologyAlzheimer's diseaseANU-ADRI

Comparative Performance of Dementia Risk Indices in the HUNT Study: Insights into CogDrisk, LIBRA, CAIDE, and More

By MedXY|Oct 21, 2025

This study compares five dementia risk indices using data from the HUNT study, revealing CogDrisk as the most accurate predictor, though none outperformed a demographics-only model including age and education.

Rapamycin for Alzheimer’s Prevention in APOE4 Carriers: Restoring Brain Metabolism and Vascular Health
NeurologyAlzheimer's diseaseAPOE4

Rapamycin for Alzheimer’s Prevention in APOE4 Carriers: Restoring Brain Metabolism and Vascular Health

By MedXY|Oct 21, 2025

Rapamycin shows promise in preventing Alzheimer’s disease in APOE4 carriers by improving brain mitochondrial function, synaptic activity, and vascular health, highlighting a potential genotype-targeted early intervention for this high

Lifetime Walking Intensity and Duration Reduce Amyloid-β Accumulation in Alzheimer’s Disease: Insights from a Korean Longitudinal Cohort
Family Medicine & NutritionAlzheimer's diseaseAmyloid-β

Lifetime Walking Intensity and Duration Reduce Amyloid-β Accumulation in Alzheimer’s Disease: Insights from a Korean Longitudinal Cohort

By MedXY|Oct 20, 2025

A 4-year longitudinal study reveals that long-duration, high-intensity lifetime walking is associated with reduced amyloid-β accumulation in older adults, suggesting a neuroprotective effect when initiated early in life.

Moderate-to-Vigorous Physical Activity, p-tau181, and Cognition in Older Adults with Memory Complaints: Insights from the MAPT Study
NeurologyagingAlzheimer's disease

Moderate-to-Vigorous Physical Activity, p-tau181, and Cognition in Older Adults with Memory Complaints: Insights from the MAPT Study

By MedXY|Oct 20, 2025

Higher moderate-to-vigorous physical activity slows p-tau181 increase, a marker of Alzheimer’s pathology, but elevated p-tau181 diminishes exercise-related cognitive benefits in older adults.

Blood Biomarkers of Alzheimer’s Disease Predict Long-Term Muscle Strength Decline in Older Adults
Internal MedicineagingAlzheimer's disease

Blood Biomarkers of Alzheimer’s Disease Predict Long-Term Muscle Strength Decline in Older Adults

By MedXY|Oct 20, 2025

This study links Alzheimer’s disease-related blood biomarkers with accelerated muscle strength loss over 12 years, highlighting the interplay between neurodegeneration and physical decline in aging populations.

Advances in Alzheimer’s Diagnosis: A Comprehensive Review of CSF and Blood Biomarkers
NeurologyAlzheimer's diseaseblood-based biomarkers

Advances in Alzheimer’s Diagnosis: A Comprehensive Review of CSF and Blood Biomarkers

By MedXY|Oct 20, 2025

This article reviews a systematic meta-analysis of 15 cerebrospinal fluid and blood biomarkers for Alzheimer’s disease, highlighting robust diagnostic performance of core markers T-tau, P-tau, and Aβ42 in clinical practice and researc

Assessing the Role of Kidney Function in Alzheimer’s Disease Blood Biomarker Interpretation and Amyloid-β Positivity Prediction
NephrologyAlzheimer's diseaseamyloid-β positivity

Assessing the Role of Kidney Function in Alzheimer’s Disease Blood Biomarker Interpretation and Amyloid-β Positivity Prediction

By MedXY|Oct 20, 2025

Kidney function influences certain Alzheimer’s disease blood biomarker levels but, within normal to mild impairment ranges, does not improve prediction of amyloid-β positivity, supporting the clinical utility of blood biomarkers in AD

Brexpiprazole in Alzheimer’s Disease-Related Agitation: Modest Gains Amidst Safety Uncertainties
NeurologyagitationAlzheimer's disease

Brexpiprazole in Alzheimer’s Disease-Related Agitation: Modest Gains Amidst Safety Uncertainties

By MedXY|Oct 12, 2025

This review evaluates brexpiprazole’s efficacy and safety for agitation in Alzheimer’s disease, revealing modest symptom improvement but uncertain safety profiles, underscoring the need for individualized therapy and further res

Alzheimer’s Disease: Navigating Controversies and Shaping Future Strategies
NeurologyAlzheimer's diseasebiomarkers

Alzheimer’s Disease: Navigating Controversies and Shaping Future Strategies

By MedXY|Oct 10, 2025

Recent advances in anti-β amyloid monoclonal antibodies offer promising reductions in Alzheimer’s disease progression but spark debate regarding their clinical impact, cost-effectiveness, and accessibility. Emerging biomarkers and preventiv

Clinically Meaningful Changes in Cognitive and Functional Measures Early in Alzheimer’s Disease: Insights from Population-Based Cohorts
Clinical UpdatesAlzheimer's diseasecognitive aging

Clinically Meaningful Changes in Cognitive and Functional Measures Early in Alzheimer’s Disease: Insights from Population-Based Cohorts

By MedXY|Oct 9, 2025

This review synthesizes evidence on clinically meaningful within-patient changes in cognitive and functional assessments among individuals transitioning to mild cognitive impairment (MCI), highlighting implications for clinical trials and e

Promising Links Between Diabetes Medications and Alzheimer’s Disease Risk Reduction
Clinical UpdatesAlzheimer's diseaseGLP-1 receptor agonists

Promising Links Between Diabetes Medications and Alzheimer’s Disease Risk Reduction

By MedXY|Oct 9, 2025

Recent real-world data suggest GLP-1 receptor agonists and SGLT2 inhibitors may lower Alzheimer’s disease risk more effectively than DPP-4 inhibitors, highlighting the need for randomized trials to confirm potential neuroprotective benefits

Anti-Inflammatory Diet and Alzheimer’s Disease Mortality: Insights from a National Cohort Study
Family Medicine & NutritionAlzheimer's diseaseAnti-inflammatory Diet

Anti-Inflammatory Diet and Alzheimer’s Disease Mortality: Insights from a National Cohort Study

By MedXY|Oct 6, 2025

Higher adherence to an anti-inflammatory diet is linked to lower all-cause mortality and a trend toward reduced Alzheimer’s disease mortality, particularly among men and non-Hispanic Whites, highlighting dietary modification as a pote

Genotype-Specific Metabolic Insights and Mediterranean Diet Impact on Dementia Risk and Cognitive Health
Clinical UpdatesAlzheimer's diseaseMediterranean diet

Genotype-Specific Metabolic Insights and Mediterranean Diet Impact on Dementia Risk and Cognitive Health

By MedXY|Oct 6, 2025

This article explores how genetic variants, plasma metabolites, and Mediterranean diet adherence interplay in modulating dementia risk and cognitive function, highlighting precision nutrition approaches for Alzheimer’s disease prevention.

Precision Nutrition: Can the Mediterranean Diet Reduce Alzheimer’s Risk in APOE4 Carriers?
Family Medicine & NutritionAlzheimer's diseaseAPOE4

Precision Nutrition: Can the Mediterranean Diet Reduce Alzheimer’s Risk in APOE4 Carriers?

By MedXY|Oct 6, 2025

A large prospective study reveals that adherence to a Mediterranean diet significantly lowers dementia risk, especially in individuals carrying two copies of the APOE4 gene associated with Alzheimer’s disease, highlighting the potential of

Prev
3 / 4
1234
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities